2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
United States
781 552 4452
https://www.bonebiologics.com
Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 2
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jeffrey Frelick | CEO & President | 325k | N/D | 1966 |
Ms. Deina H. Walsh | Chief Financial Officer | 212,5k | N/D | 1964 |
Dr. Shun'ichi Kuroda | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
L'ISS Governance QualityScore di Bone Biologics Corporation al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.